Sign in and upgrade to a paid plan to export dividends as CSV.
Sign in and upgrade to a paid plan to export price history as CSV.
Sign in and upgrade to a paid plan to export financials as CSV.

Cresanto Global Limited

Healthcare · Pharmaceuticals & Biotechnology

BSE: 531207
₹5.37
▲ 0.00 (0.00%)
Sept. 21, 2026 · BSE · bse_bhavcopy
Quality
14/100
Weak
Valuation
—/100
Data unavailable
Momentum
98/100
Bullish

Tradinity's own scoring, not a copy of any third party's -- see the Key Metrics section for the real ratios behind each number.

Key Metrics

Market Capitalization
₹2 Cr
PE (TTM)
Data unavailable.
Price to Book
-0.8
PEG (TTM)
Data unavailable (needs 8 quarters of EPS).
Institutions holding %
Data unavailable.
Piotroski Score
Data unavailable.
Relative return vs Nifty50, qtr %
Data unavailable.
Relative return vs Sector, qtr %
124.7
Free Cash Flow
₹-0 Cr
as of March 31, 2026
Industry median ₹-0 Cr (198 companies)
EPS Growth (YoY)
-443.75%
as of March 31, 2026
Industry median 26.14% (180 companies)
Net Profit Growth (TTM)
-37.37%
as of June 30, 2026
Industry median 6.21% (175 companies)
Operating Revenue Growth (TTM)
13.76%
as of June 30, 2026
Industry median 9.08% (175 companies)
Profit Growth (YoY)
35.87%
as of June 30, 2026
Industry median 22.20% (176 companies)
Revenue Growth (YoY)
33.33%
as of March 31, 2012
Industry median 14.05% (173 companies)
Current Ratio
0.04
as of March 31, 2026
Industry median 1.84 (197 companies)
Debt to Equity
-0.93
as of March 31, 2026
Industry median 0.14 (186 companies)
Interest Coverage
-1.50
as of June 30, 2026
Industry median 10.58 (182 companies)
Net Margin
-16.67%
as of Sept. 30, 2025
Industry median 9.35% (179 companies)
Operating Margin (EBIT)
-16.67%
as of Sept. 30, 2025
Industry median 14.22% (181 companies)
Operating Margin (TTM)
-110.88%
as of June 30, 2026
Industry median 12.41% (182 companies)
Return on Assets
-4343.43%
as of March 31, 2026
Industry median 5.54% (180 companies)
Return on Capital Employed
128.15%
as of March 31, 2026
Industry median 12.43% (181 companies)
Return on Equity
14.25%
as of March 31, 2026
Industry median 9.66% (179 companies)

Investment checklist

Tradinity's own yes/no questions with the rule stated beside each. “Items without enough data are left out, never counted as a No, and the totals count only answered questions. A summary of numbers on this page, not advice.

Financials

3 of 6 met
  • No Net profit is higher than a year earlier in each of the last 4 quarters
  • No Quality score is Strong (70 or more)
  • Yes Debt to equity is below 0.5 (-0.93)
  • No Return on equity is 15% or more (14.2%)
  • Yes Net cash flow for the latest year is positive
  • Yes Cash from operations is higher than the year before

Ownership

2 of 3 met
  • No FII/FPI or DII holding rose in the latest quarter
  • Yes Promoter holding rose or was unchanged in the latest quarter
  • Yes Promoter pledge is 5% of their holding or less and not rising (0.0% pledged)

Peer comparison

3 of 3 met
  • Yes 1-year return beats the industry median
  • Yes Revenue growth beats the industry median
  • Yes Profit growth beats the industry median

Value and momentum

3 of 4 met
  • Yes Momentum score is Bullish (70 or more)
  • Yes Price is above the 5, 10 and 20 day averages
  • Yes Price is above the 50, 100 and 200 day averages
  • No Latest candle has a bullish shape (hammer, dragonfly doji, white marubozu)

Price

Download CSV

PE/EPS use each quarter's real filed EPS only from 45 days after quarter-end (no look-ahead) against the raw close of the day. Price-to-book isn't a mode here: the feed has no dated share count, so there's no real history to chart.

Relative Returns (vs SENSEX)

Prices adjusted for splits and bonuses. * = a corporate action affecting this date could not be parsed and is not reflected.

Price range

Day return
0.0%
Low 5.3700 · High 5.3700
1W return
4.9%
Low 5.3700 · High 5.3700
1M return
4.9%
Low 5.1200 · High 5.3700
52W return
124.7%
Low 5.1200 · High 5.3700
Lifetime High ₹39.5300 (July 28, 2011)
Lifetime Low ₹0.9200 (June 7, 2021)

Full price history and technicals →

EMA & SMA

Bullish6
Bearish0
5D
4.9
10D
4.2
20D
3.5
50D
2.7
100D
2.3
200D
2.1

Delivery and volume

Day avg. delivery
100.0%
Week avg. delivery
100.0%
Month avg. delivery
100.0%

Week = 5 sessions, Month = 22 sessions ending the latest trading day — the same combined NSE+BSE delivery data as the table below, just summed.

Resistance and support

5.37
Pivot
First resistance5.37
Second resistance5.37
Third resistance5.37
First support5.37
Second support5.37
Third support5.37
Day RSI93.5
Day MFI26.1
Day MACD0.75
Day MACD signal0.41

Beta

1M—
3M—
1Y—
3Y—

Price change analysis

↑ 4.9%
Over 1 Month
LowHigh
5.125.37
↑ 124.7%
Over 3 Months
LowHigh
5.125.37
↑ 124.7%
Over 6 Months
LowHigh
5.125.37
↑ 124.7%
Over 1 Year
LowHigh
5.125.37
Legend Positive indicator Neutral indicator Negative indicator

Buy/Sell Zone

View Buy/Sell Zone →

Data unavailable (needs at least 2 historical quarters with both a filed EPS and a matching trading day).

Revenue (June 30, 2026)
₹— Cr
Net profit (June 30, 2026)
₹-0 Cr
Basic EPS (June 30, 2026)
₹-0.1400

Ranks #183 of 184 in Pharmaceuticals & Biotechnology by market cap -- full peer table on the Financials page.

Shareholding pattern / Ownership

Shareholding summary

Jun 2026
  • Promoter32.27%

Largest holders

Data unavailable.

Historical promoter holding

Promoters holdings were unchanged at 32.27% in Jun 2026 qtr

All shareholding details →

DateClientDealActionQuantityPriceExchange
10 Jan 2019 GIRISHCHANDRA JAYANTILAL PAREKH Bulk Buy 45,000 2.1900 BSE
10 Jan 2019 MUKESH K BHANUSHALI Bulk Sell 45,001 2.1900 BSE
3 Apr 2018 KIRTIKUMAR MANGALDAS SHAH Bulk Sell 25,700 2.2600 BSE
3 Apr 2018 MUKESH K BHANUSHALI Bulk Buy 25,700 2.2600 BSE
18 Feb 2015 TOPNOTCH INVESTMENTS PRIVATE LIMITED Bulk Buy 42,000 5.0000 BSE
14 Mar 2013 SCRIPTECH WEALTH MANAGEMENT SERVICES PRIVATE LIMITED Bulk Buy 23,658 8.4400 BSE
18 Feb 2013 SUNITA DEVI SANGTANI Bulk Sell 40,000 14.9900 BSE
15 Feb 2013 SHELLEY AGGARWAL Bulk Sell 90,000 15.6000 BSE
14 Dec 2012 RESURGENCE ADVISORY SERVICES Bulk Buy 25,000 15.5500 BSE
27 Nov 2012 SWATI AMRISH SHAH Bulk Buy 25,000 24.3200 BSE

All bulk and block deals →

Corporate Actions

Full history (1 events) →

Bonuses, splits, buybacks and other events. Dividends are listed separately above.

Ex-dateTypeSubject
—NAME_CHANGEName changed from Raymed Labs. Ltd. to Cresanto Global Limited

All corporate actions →

Corporate Announcements

All 1 announcements, with search →

Exchange disclosures (NSE and BSE), most recent first.

DateCategoryAnnouncement
28 Sep 2026 Insider Trading / SAST Cresanto Global Ltd - 531207 - Closure of Trading Window

All announcements →

SWOT

Tradinity's own rule-based read of the real ratios elsewhere on this page -- not a copy of any third party's, and never a forward-looking prediction.

Strengths

  • Strong revenue growth YoY (33.3%)

Weaknesses

  • Thin net profit margin (-16.7%)
  • Negative shareholder equity (Debt/Equity -0.93) -- accumulated losses exceed paid-in capital
  • Tight liquidity (Current Ratio 0.04)

Opportunities

Data unavailable.

Threats

  • RSI in overbought territory (93.5)
  • Weak interest coverage (-1.5x) -- limited cushion against rising rates

Data unavailable (no single-stock futures or options activity on record for this company).

Frequently asked questions about Cresanto Global Limited

Where is the share price?

The price at the top of this page is the last traded price from exchange data; during market hours it refreshes on its own. The Chart & Technicals section has the full price history.

Where are the financial results?

The Financials page has quarterly and annual results, ratios, cash flow and the balance sheet, on a standalone or consolidated basis.

Who owns the company?

The Ownership section shows the latest shareholding pattern from exchange filings, with promoter, FII, DII and public holdings by quarter.

Does Tradinity give buy or sell advice?

No. The scores and checklist on this page are rule-based summaries of published figures, not recommendations. Tradinity is not a registered investment adviser.